News

The purpose of this study is to determine whether PXT-3003 is effective and well tolerated in patients with CMT1A. PXT-3003 is a novel oral fixed-low dose combination of

Under the terms of the agreement, Evotec will complement Spero’s capabilities by providing early-stage research support for key projects such as Spero’s Potentiator programme which is focused on

The Resolve trial is a randomized, observer-blinded, placebo-controlled trial of 11,850 older adults at 60 sites in the United States. All participants have been enrolled and vaccinated in

MAT2501 is an orally-administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic agent amikacin which may be used to treat different types of multidrug-resistant bacteria, including NTM and

The company also announced that the KRAS mutant NSCLC arm will not advance to the second stage. The rationale for these decisions is based on safety and efficacy

The active IND now allows the Company to initiate its planned Phase 3 program for ZX008. Zogenix president and CEO Stephen Farr said: "We are pleased to have

The study is being conducted at The University of Texas MD Anderson Cancer Center and is being led by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical

Acute kidney injury (AKI) is a serious medical condition characterized by an abrupt loss of kidney function. AKI is estimated to affect up to 18 percent of hospital

The Wall Street Journal had recently reported that AstraZeneca was looking to acquire Acerta for over $5bn to secure access to its experimental blood cancer drug, acalabrutinib. AstraZeneca